Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 111-120

  García Gutiérrez, María S ^a   Manzanares, Jorge ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Benzodiazepines; cannabinoid CB2r; CRF gene expression; GABAA 2; GABAA 2; POMC gene expression; transgenic mice

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ALPRAZOLAM; CANNABINOID 2 RECEPTOR; CORTICOTROPIN RELEASING FACTOR; MESSENGER RNA; PROOPIOMELANOCORTIN;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARCUATE NUCLEUS; ARTICLE; DOSE RESPONSE; GENE OVEREXPRESSION; HIPPOCAMPUS; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS; IMMOBILIZATION STRESS; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; WILD TYPE;

ALPRAZOLAM; AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; GENE EXPRESSION; HIPPOCAMPUS; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; MOTOR ACTIVITY; PHOTOPERIOD; RECEPTOR, CANNABINOID, CB2; RECEPTORS, GABA-A; RESTRAINT, PHYSICAL; RNA, MESSENGER;

EID: 78650595351     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110379507     Document Type: Article

References (61)

1. Altemus M., Pigott T., Kalogeras KT, Demitrack M., Dubbert B., Murphy DL, et al. (1992) Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 49: 9-20.
2. Arborelius L., Owens MJ, Plotsky PM and Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160: 1-12.
3. Aso E., Ozaita A., Valdizán EM, Ledent C., Pazos A., Maldonado R., et al. (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105: 565-572.
4. Banki CM, Karmacsi L., Bissette G. and Nemeroff CB (1992) Cerebrospinal fluid neuropeptides in dementia. Biol Psychiatry 32: 452-456.
5. Benito C., Núñez E., Tolón RM, Carrier EJ, Rábano A., Hillard CJ, et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136-11141.
6. Benito C., Romero JP, Tolón RM, Clemente D., Docagne F., Hillard CJ, et al. (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27: 2396-2402.
7. Bremner JD, Licinio J., Darnell A., Krystal JH, Owens MJ, Southwick SM, et al. (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154: 624-629.
8. Chappell P., Leckman J., Goodman W., Bissette G., Pauls D., Anderson G., et al. (1996) Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 39: 776-783.
9. Connolly CN, Krishek BJ, McDonald BJ, Smart TG and Moss SJ (1996) Assembly and cell surface expression of heteromeric and homomeric γ-aminobutyric acid type A receptors. J Biol Chem 271: 89-96.
10. Corchero J., Fuentes JA and Manzanares J. (1999) Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 64: 905-911.
11. Cota D., Steiner MA, Marsicano G., Cervino C., Herman JP, Grübler Y., et al. (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148: 1574-1581.
12. Crawley J. and Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167-170.
13. Da Settimo F., Taliani S., Trincavelli ML, Montali M. and Martini C. (2007) GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 14: 2680-2701.
14. Devane WA, Dysarz FA III, Johnson MR, Melvin LS and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
15. Dunn AJ and Berridge CW (1990) Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses ? Brain Res Brain Res Rev 15: 71-100.
16. Finn DP, Jhaveri MD, Beckett SR, Kendall DA, Marsden CA and Chapman V. (2004) Cannabinoids modulate ultrasound-induced aversive responses in rats. Psychopharmacology 172: 41-51.
17. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G. and Nemeroff CB (1996) Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 39: 703-707. (Pubitemid 26157605)
18. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
19. García-Gutiérrez MS and Manzanares J. (2009) Resistant depressive-like behaviours in transgenic mice overexpressing cannabinoid CB2 receptors. 39th Annual Meeting of the Society for Neuroscience, Society for Neuroscience, Poster Session, 342.15 / P 14.
20. García-Gutiérrez MS, Pérez-Ortiz JM, Gutiérrez-Adán A. and Manzanares J (2010) Depression-resistant endophenotype in mice overexpressing cannabinoid CB2 receptors. Br J Pharmacol 160 (7). 1773-1784.
21. Gong J. -P, Onaivi ES, Ishiguro H., Liu Q. -R, Tagliaferro PA, Brusco A., et al. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23. (Pubitemid 43255471)
22. Gorrie GH, Vallis Y., Stephenson A., Whitfield J., Browning B., Smart TG, et al. (1997) Assembly of GABAA receptors composed of α1 and β2 subunits in both cultured neurons and fibroblasts. J Neurosci 17: 6587-6596.
23. Guzmán M., Sánchez C. and Galve-Roperh I. (2001) Control of the cell survival/death decision by cannabinoids. J Mol Med 78: 613-625.
24. Haller J., Bakos N., Szirmay M., Ledent C. and Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395-1398.
25. Haller J., Varga B., Ledent C., Barna I. and Freund TF (2004) Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19: 1906-1912.
26. Heim C., Ehlert U. and Hellhammer DH (2000) The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 25: 1-35.
27. Heim C., Owens MJ, Plotsky PM and Nemeroff CB (1997) The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Ann N Y Acad Sci 821: 194-207.
28. Herkenham M., Lynn AB, Johnson MR, Melvin LS, de Costa BR and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
29. Jolkkonen J., Lepola U., Bissette G., Nemeroff C. and Riekkinen P. (1993) CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 33: 136-138.
30. Joosten M., Valk PJ, Jordà MA, Vankan-Berkhoudt Y., Verbakel S., van den Broek M., et al. (2002) Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp hematol 30: 142-149.
31. Kittler JT, Wang J., Connolly CN, Vicini S., Smart TG and Moss SJ (2000) Analysis of GABAA receptor assembly in mammalian cell lines and hippocampal neurons using γ2 subunit green fluorescent protein chimeras. Mol Cell Neurosci 16: 440-452.
32. Kvetnansky R., Mitro A., Mikulaj L. and Hocman G. (1966) [Catecholamines in the adrenal medulla and morphological changes of the adrenal medulla in the course of adaptation to repeated immobilization stress]. Bratisl Lek Listy 46: 35-41.
33. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185.
34. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) Method. Methods 25: 402-408.
35. Löw K., Crestani F., Keist R., Benke D., Brünig I., Benson JA, et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290: 131-134.
36. Mackie K. (2005) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
37. Manzanares J., Corchero J. and Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats. Brain Res 839: 173-179.
38. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
39. Morgan NH, Stanford IM and Woodhall GL (2009) Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57: 356-368.
40. Munro S., Thomas KL and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
41. Onaivi ES (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54: 231-246.
42. Onaivi ES, Ishiguro H., Gong JP, Patel S., Meozzi PA, Myers L., et al. (2008 a) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 3: e1640.
43. Onaivi ES, Ishiguro H., Gong J. -P, Patel S., Meozzi PA, Myers L., et al. (2008 b) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 1139: 434-449.
44. Palkovits M. (1983) Punch sampling biopsy technique. Methods enzymol 103: 368-376.
45. Patel S., Roelke CT, Rademacher DJ, Cullinan WE and Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145: 5431-5438.
46. Paxinos G. and Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. New York: Academic Press. Harcourt Science and Technology Company.
47. Pritchett DB, Lüddens H. and Seeburg PH (1989) Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science 245: 1389-1392.
48. Racz I., Nadal X., Alferink J., Baños JE, Rehnelt J., Martín M., et al. (2008 a) Interferon-γ is a critical modulator of CB2 cannabinoid receptor signaling during neuropathic pain. J Neurosci 28: 12136-12145.
49. Racz I., Nadal X., Alferink J., Baños JE, Rehnelt J., Martín M., et al. (2008 b) Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28: 12125-12135.
50. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W., Chrousos GP and Gold PW (1986) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143: 896-899.
51. Smith GW, Aubry JM, Dellu F., Contarino A., Bilezikjian LM, Gold LH, et al. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
52. Steiner MA, Marsicano G., Nestler EJ, Holsboer F., Lutz B. and Wotjak CT (2008) Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33: 54-67.
53. Steiner MA and Wotjak CT (2008) Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170: 397-432.
54. Stenzel-Poore MP, Heinrichs SC, Rivest S., Koob GF and Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior. J Neurosci 14: 2579-2584.
55. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul JM, Stalla GK, et al. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19: 162-166.
56. Tsou K., Brown S., Sañudo-Peña MC, Mackie K. and Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411.
57. Urigüen L., Pérez- Rial S., Ledent C., Palomo T. and Manzanares J. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973.
58. Whiting PJ (2003) The GABAA receptor gene family: New opportunities for drug development. Curr Opin Drug Discov Devel 6: 648-657.
59. Yehuda R. (1997) Sensitization of the hypothalamic-pituitary-adrenal axis in posttraumatic stress disorder. Ann N Y Acad Sci 821: 57-75. (Pubitemid 27343011)
60. Yiangou Y., Facer P., Durrenberger P., Chessell IP, Naylor A., Bountra C., et al. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC neurology 6: 12.
61. Young WS III, Mezey E. and Siegel RE (1986) Vasopressin and oxytocin mRNAs in adrenalectomized and Brattleboro rats: analysis by quantitative in situ hybridization histochemistry. Brain Res 387: 231-241.